Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

[1]  P. Bie,et al.  Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. , 2014, Toxicology letters.

[2]  B. Karlan,et al.  A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer , 2013, Clinical Cancer Research.

[3]  A. Godwin,et al.  Correction: Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum , 2013, PLoS ONE.

[4]  W. Nishio,et al.  Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells , 2013, Cancer medicine.

[5]  Sheila M. Reynolds,et al.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.

[6]  N. Matsumura,et al.  PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction , 2013, Clinical Cancer Research.

[7]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[8]  R. Ozols,et al.  Reclassification of serous ovarian carcinoma by a 2‐tier system , 2012, Cancer.

[9]  D. Matei,et al.  Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer , 2012, Oncogene.

[10]  Paulo A. S. Nuin,et al.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer , 2012, BMC Cancer.

[11]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[12]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[13]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[14]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[15]  Kou-Juey Wu,et al.  Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer , 2010, Clinical Cancer Research.

[16]  Ituro Inoue,et al.  Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.

[17]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[18]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[19]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[20]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[21]  Robert S Mannel,et al.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[23]  C. Caldas,et al.  The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel , 2007, Cancer cell.

[24]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[25]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[27]  Brigitte M. Ronnett,et al.  The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[28]  I. Shih,et al.  Diverse tumorigenic pathways in ovarian serous carcinoma. , 2002, The American journal of pathology.

[29]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[30]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[31]  N. Dubrawsky.  Cancer statistics , 2022 .